OrbiMed’s Intellia Therapeutics NTLA Stock Holding History

OrbiMed’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-164,627	Closed	-$6.14M	–	131
2023 Q1	$6.14M	Buy	+164,627	New	+$6.46M	0.12%	100
2022 Q1	–	Sell	-53,200	Closed	-$6.29M	–	160
2021 Q4	$6.29M	Hold	53,200	–	–	0.08%	129
2021 Q3	$7.14M	Buy	+53,200	New	+$8.05M	0.08%	144
2021 Q2	–	Sell	-72,500	Closed	-$5.82M	–	173
2021 Q1	$5.82M	Buy	+72,500	New	+$4.87M	0.05%	136
2020 Q3	–	Sell	-137,100	Closed	-$2.88M	–	155
2020 Q2	$2.88M	Sell	137,100 -125,000	-48%	-$2.12M	0.04%	129
2020 Q1	$3.21M	Hold	262,100	–	–	0.05%	117
2019 Q4	$3.85M	Sell	262,100 -65,500	-20%	-$911K	0.05%	108
2019 Q3	$4.37M	Hold	327,600	–	–	0.08%	97
2019 Q2	$5.36M	Sell	327,600 -50,000	-13%	-$786K	0.08%	110
2019 Q1	$6.45M	Hold	377,600	–	–	0.1%	103
2018 Q4	$5.15M	Sell	377,600 -367,000	-49%	-$6.82M	0.1%	100
2018 Q3	$21.3M	Sell	744,600 -131,400	-15%	-$3.82M	0.26%	86
2018 Q2	$24M	Sell	876,000 -237,000	-21%	-$5.74M	0.29%	83
2018 Q1	$23.5M	Sell	1,113,000 -1,224,684	-52%	-$30.1M	0.29%	78
2017 Q4	$44.9M	Sell	2,337,684 -324,496	-12%	-$7.49M	0.57%	51
2017 Q3	$66.2M	Hold	2,662,180	–	–	0.63%	48
2017 Q2	$42.6M	Hold	2,662,180	–	–	0.45%	61
2017 Q1	$37.5M	Hold	2,662,180	–	–	0.43%	61
2016 Q4	$34.9M	Hold	2,662,180	–	–	0.44%	55
2016 Q3	$45.3M	Hold	2,662,180	–	–	0.52%	52
2016 Q2	$56.8M	Buy	+2,662,180	New	+$70.8M	0.59%	49

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OrbiMed's NTLA Position: Q2 2023 in Review

OrbiMed sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 164,627 shares — an estimated $6.14M sold.

OrbiMed first reported a position in NTLA in Q2 2016 and held it in 21 quarters. The position peaked at $66.2M in Q3 2017. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

OrbiMed reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
OrbiMed sold 164,627 Intellia Therapeutics shares in Q2 2023, an estimated $6.14M.
OrbiMed first reported a position in Intellia Therapeutics in Q2 2016 and held it in 21 quarters.
OrbiMed's Intellia Therapeutics position peaked at $66.2M in Q3 2017.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.